Rome, September 24 - 27, 2017

With an educational support of:

Monday, September 25, 2017

Educational Session - Biology, diagnosis and management of APL

Chairmen: M. Alcalay, M.A. Sanz

L. Cicconi

Pathogenesis, diagnosis and monitoring of Acute Promyelocytic Leukemia

P. Montesinos

Front-line Therapy in Acute Promyelocytic Leukemia

L. Ades

Acute Promyelocytic Leukemia Therapy of relapse

Session V - Molecular bases of targeted therapy and resistance

Chairmen: F. Grignani, W.H. Miller

P. G. Pelicci

Regulation of self renewal in cancer stem cells

M. Giannì

The S100 calcium binding protein A3 binds directly and specifically to RARα and PML-RAR and modulates the activity of APL cells

Session VI - Genome and epigenome of APL

Chairmen: L. Degos, P.G. Pelicci

W. H. Miller

Mechanisms of response and resistance to epigenetic therapies

Oral Session I - APL biology I

Chairmen: S. Minucci, C. Nervi

C. Bally

Whole exome analysis of relapsing patients with Acute Promyelocytic Leukemia

L. Iaccarino

PML and RARA mutations in relapsed Acute Promyelocytic Leukemia

O. H. Krämer

Molecular analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in Acute Promyelocytic Leukemia cells

M. S. Tallman

Mutations in Acute Promyelocytic Leukemia are Similar at Diagnosis and Relapse and ETV6 may be a Molecular Biomarker of Decreased Disease-Free Survival and High-Risk Disease Independent of White Blood Cell Count

R. Kolhe

Acute Promyelocytic Leukemia: molecular characterization by cancer immune profiling may identify patients at risk of early death

Session VII - Early death and population-based studies

Chairmen: B. Löwenberg, E. Rego

M. Seftel

Observational studies in APL: what have we learned and what can we still learn?

S. Lehmann

Early deaths as the most significant threat to APL patients in real life

H. H. Zhu

Early Death and Outcomes of Patients with APL using arsenic and ATRA as First-Line treatment: a real world study

F. Ravandi

Long-term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

Session VIII - Management of APL in developing countries I

Chairmen: N. Berliner, L. Adès

E. Rego

Long term follow up of the International Consortium on Acute Promyelocytic Leukemia: achievements and limitations

M. Chandy

Progress and Constraints in treating APL in India

M. Saidi

Epidemiology, diagnosis, clinical features and outcome of APL patients treated in Batna Against Cancer Center (Algeria)

D. Freigeiro

Pediatric acute promyelocytic leukemia (apl) in latin american children. is it possible to work together? The Clehop initiative

Teva sponsored symposium Next-generation APL leaders: Teva's award for young hematologists

Chairman: B. Löwenberg

H. De Thé

Arsenic, a targeted curative therapy of APL

Tuesday, September 26, 2017

Oral Session II - APL biology II

Chairmen: S.K. Hasan, C. Thiede

S. Masciarelli

Retinoic Acid and Arsenic Trioxide sensitize Acute Myeloid Leukemia cells to ER stress

N. I. Noguera

PML-RARa interferes with Nrf2 function in Acute Promyelocytic Leukemia Cells

M. Llop

Molecular analysis of acute promyelocytic leukemia by next generation sequencing

N. Balasundaram

Metabolic catastrophe of arsenic trioxide resistant cells in Acute Promyelocytic Leukemia

J. Labrador

Clinical significance of complex karyotype at diagnosis in Patients with Acute Promyelocytic Leukemia Treated with ATRA and chemotherapy based PETHEMA trials

Session IX - Update in frontline trials I

Chairmen: M. Seftel, M.S. Tallman

G. Avvisati

Update of the Italian-German study APL 0406

J. Li

Retinoic Acid and Arsenic Trioxide with or without Chemotherapy for Acute Promyelocytic Leukemia with Different Risk Stratifications: An Interim Analysis of China APL 2012 Study

A. Takeshita

Recent results from the prospective studies on APL in the Japan Adult Leukemia Study Group (JALSG)

L. Adès

Update of APL 2006 trial results

M. A. Sanz

Update on PETHEMA trials

Session X - Update in frontline trials II

Chairmen: M. Seftel, M. Tallman

H. Iland

The ALLG approach to incorporating arsenic trioxide: APML4 (final analysis) and APML5 (encapsulating therapy)

V. Mathews

Potential for non-conventional agents in upfront and relapsed APL

N. Russell

Long term follow up of the NCRI AML17 trial of attenuated arsenic trioxide and ATRA therapy for newly diagnosed and relapsed Acute Promyelocytic Leukaemia

E. Estey

Implications for AML Raised by “Chemofree” ATO+ATRA in APL

Session XI - The APL coagulopathy

Chairmen: G. Avvisati, M. Chandy

A. Falanga

APL fatal bleeding and thrombosis in the ATRA era

P. Montesinos

Thrombohemorrhagic disorders in APL: the unsolved issue

M. Frech

Differential expression of tissue factor F3 and nuclear receptors 4A in early death acute promyelocytic leukemia patients

H. H. Zhu

The impact of oral arsenic and ATRA on conagulopathy in APL

Session XII - APL in children and the elderly

Chairmen: R.A. Larson, F. Locatelli

O. Abla

Obesity and Initial High White Blood Cell Count Are Predictors of Thrombo-hemorrhagic Early Death in Children and adolescents with t(15;17) positive Acute Promyelocytic Leukemia

A. Testi

Risk-adapted ATRA and chemotherapy in children with newly diagnosed acute promyelocytic leukemia: a 15-year multicentric experience

D. Martínez Cuadrón

Characteristics and outcome of elderly APL patients treated with PETHEMA protocols

M. Kutny

Toxicity in Pediatric Patients Treated with ATRA and Arsenic Trioxide Induction: A Report from the Children's Oncology Group Study AAML1331

Oral Session III - APL in children and elderly

Chairmen: H. Iland, N. Russell

S. Al-Hadad

Outcome of acute promyelocytic leukemia patients Experience of Children Welfare Teaching Hospital (2010-2015) Baghdad, Iraq

H. H. Zhu

Oral arsenic and retinoic acid for children with non-high-risk APL

M. A. Kutny

Arsenic Trioxide Consolidation Results in Excellent Survival in Young Children as well as Older Children and Adolescents with Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631

L. Adès

Arsenic Trioxide (ATO) and ATRA with Limited Chemotherapy (CT) in Newly Diagnosed Standard Risk APL in the Elderly. a Report By the French Belgian Swiss APL Group (APL 2006 trial)

L. B. Huang

Comparing Arsenic Trioxide with Realgar-Indigo naturalis formula in children with Acute Promyelocytic Leukemia: An Interim Report of Multicenter and Randomized clinical Trial

Oral Session IV - Clinical studies and prognostic factors

Chairmen: L. Degos, S. Lehmann

E. Lengfelder

Frontline therapy of acute promyelocytic leukemia: randomized comparison of ATRA and intensified chemotherapy including high dose cytosine-arabinoside versus ATRA and anthracyclines - A prospective multicenter randomized clinical trial of the German Acute Myeloid Leukemia Cooperative Group (AMLCG).

H. H. Zhu

Oral arsenic and retinoic acid for high-risk Acute Promyelocytic Leukemia

B. Boluda

Clinical significance of CD56 expression in patients with de novo acute promyelocytic leukemia treated with the PETHEMA LPA96, LPA99 and LPA2005 protocols: an updated analysis

R. Rodriguez-Veiga

Characteristics and clinical outcome of patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

T. Maia

Retrospective analysis of early mortality in a cohort of patients with Acute Promyelocytic Leukemia

Wednsday, September 27, 2017

Session XIII - Management of relapse and role of stem cell transplantation

Chairmen: W. Arcese, L. Adès

E. Lengfelder

Which is the best treatment for relapsed APL?

M. Breccia

Arsenic trioxide for the management of relapsed APL patients

J. Sanz

Role of Transplantation in Acute Promyelocytic Leukemia

L. Cicconi

Prolonged ATO and ATRA therapy for relapsed acute promyelocytic leukemia

Session XIV - APL as a second tumor and t-MN after APL

Chairmen: G. Leone, P. Montesinos

R. A. Larson

Is APL occurring as a therapy-related malignancy different from de novo APL?

S. K. Hasan

Mitoxantrone related t-APL

S. Kayser

Characteristics and outcome of patients with therapyrelated Acute Promyelocytic Leukemia front-line treated with or without arsenic trioxide. An international collaboration study

P. Attias

Mutational analysis of MDS and AML occurring after treatment for acute promyelocytic leukemia (APL) - A report of 9 cases

Session XV - Quality of life and health economics

Chairmen: M. Breccia, M.A. Sanz

F. Efficace

Short and long-term quality of life in patients with Acute Promyelocytic Leukemia

H. H. Zhu

The real world of arsenic uses in Chinese with Acute Promyelocytic Leukemia: a cross-sectional survey

S. Bolds

Availability of atra, blood bank support, treatment protocols and hematologists/oncologists for management of APL in two states (michigan and lousiana) in the USA

Oral Session V - Management of APL in developing countries

Chairmen: F. Lo Coco, V. Mathews

R. Farah

A multicenter experience from Lebanon in childhood and adolescents acute myeloid leukemia: high rate of early death in childhood APL

K. Reddy

Early death rate in Acute Promyelocytic Leukemia: A single community centre experience in South India